文献速递消化道肿瘤放疗放疗物理与技术

STAR-TReC试验中直肠系膜放疗计划的多中心质量保证:荷兰结果

Radiotherapy quality assurance for mesorectum treatment planning within the multi-center phase II STAR-TReC trial: Dutch results.
PubMed 文献 · Radiat Oncol · 2020-02-18

STAR-TReC是一项国际多中心随机II期试验,评估短程放疗或长程放化疗替代全直肠系膜切除术的可行性,新靶区仅包括直肠系膜。治疗计划QA显示各中心危及器官剂量差异大,本研究分析8个中心对5例病例制定的25个2 Gy计划,并评估研究组会议对计划质量和差异的影响。结果显示初始计划OAR剂量差异大,尤其低于20 Gy剂量水平;重新计划后 bowel cavity 和膀胱剂量降低且中心间差异减小。

要点

  • 初始计划所有靶区约束均满足,但OAR剂量在中心间差异大,低剂量区尤甚。
  • 研究组会议分享初始计划DVH后,5个中心对所有病例重新计划。
  • 重新计划平均降低 bowel cavity V20Gy 12.6%、V10Gy 22.0%,膀胱V35Gy 14.7%、V10Gy 10.8%。

核心结论

  • 各中心OAR剂量差异大,尤其低于20 Gy剂量水平;研究组会议和分享初始计划结果使重新计划后OAR剂量降低且中心间差异减小。

研究设计与样本

  • 国际多中心随机II期STAR-TReC试验的治疗计划QA子研究,8个中心对5例病例制定25个2 Gy计划,OAR为bowel cavity、膀胱和股骨头,组织研究组会议讨论计划结果并允许中心重新计划。

主要发现

  • 所有初始和重新计划均满足靶区约束;初始计划OAR剂量差异大,尤其低于20 Gy剂量水平。
  • 5个中心对所有病例重新计划,1个中心未重新计划,2个中心分别对2例和3例重新计划。
  • 重新计划平均降低 bowel cavity V20Gy 12.6%、V10Gy 22.0%,膀胱V35Gy 14.7%、V10Gy 10.8%;30例重新计划中26例bowel cavity和膀胱V10Gy均降低。
  • 重新计划后bowel cavity V10Gy和V20Gy在中心间更相似。

临床怎么用

  • 多中心直肠癌直肠系膜放疗计划中,可通过研究组会议分享DVH结果并鼓励重新计划来降低OAR剂量和中心间差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The STAR-TReC trial is an international multi-center, randomized, phase II study assessing the feasibility of short-course radiotherapy or long-course chemoradiotherapy as an alternative to total mesorectal excision surgery. A new target volume is used for both (chemo)radiotherapy arms which includes only the mesorectum. The treatment planning QA revealed substantial variation in dose to organs at risk (OAR) between centers. Therefore, the aim of this study was to determine the treatment plan variability in terms of dose to OAR and assess the effect of a national study group meeting on the quality and variability of treatment plans for mesorectum-only planning for rectal cancer. METHODS: Eight centers produced 25 × 2 Gy treatment plans for five cases. The OAR were the bowel cavity, bladder and femoral heads. A study group meeting for the participating centers was organized to discuss the planning results. At the meeting, the values of the treatment plan DVH parameters were distributed among centers so that results could be compared. Subsequently, the centers were invited to perform replanning if they considered this to be necessary. RESULTS: All treatment plans, both initial planning and replanning, fulfilled the target constraints. Dose to OAR varied considerably for the initial planning, especially for dose levels below 20 Gy, indicating that there was room for trade-offs between the defined OAR. Five centers performed replanning for all cases. One center did not perform replanning at all and two centers performed replanning on two and three cases, respectively. On average, replanning reduced the bowel cavity V20Gy by 12.6%, bowel cavity V10Gy by 22.0%, bladder V35Gy by 14.7% and bladder V10Gy by 10.8%. In 26/30 replanned cases the V10Gy of both the bowel cavity and bladder was lower, indicating an overall lower dose to these OAR instead of a different trade-off. In addition, the bowel cavity V10Gy and V20Gy showed more similarity between centers. CONCLUSIONS: Dose to OAR varied considerably between centers, especially for dose levels below 20 Gy. The study group meeting and the distribution of the initial planning results among centers resulted in lower dose to the defined OAR and reduced variability between centers after replanning. TRIAL REGISTRATION: The STAR-TReC trial, ClinicalTrials.gov Identifier: NCT02945566. Registered 26 October 2016, https://clinicaltrials.gov/ct2/show/NCT02945566).

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. van den Ende RPJ, Peters FP, Harderwijk E, et al. Radiotherapy quality assurance for mesorectum treatment planning within the multi-center phase II STAR-TReC trial: Dutch results. Radiat Oncol. 2020. PMID: 32070386. doi:10.1186/s13014-020-01487-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。